Company
Relmada Therapeutics, Inc.
Headquarters: New York, NY, United States
Employees: 14
CEO: Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA
Market Cap
$11.7 Million
USD as of Jan. 1, 2025
Relmada Therapeutics, Inc. Categories
United States Healthcare Drug Manufacturers—Specialty & GenericUnited States Healthcare United States Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead program is REL-1017, is a new chemical entity and novel N-methyl-D-aspartate receptor channel blocker for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is based in Coral Gables, Florida.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Relmada Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: RLMD wb_incandescent